Anthropometric Measurements as Predictors of Low Birth Weight Among Tanzanian Neonates: A Hospital-Based Study
November 7, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Salbair Neb, Bacantus LS, Redivent, Ibires L Nexpules
Synonyms :
Levosalbutamol
Class :
Beta-2 adrenergic receptor agonist
Brand Name :
Salbair Neb, Bacantus LS, Redivent, Ibires L Nexpules
Synonyms :
Levosalbutamol
Class :
Beta-2 adrenergic receptor agonist
Dosage Forms & Strengths
Inhaler
50 mcg
Syrup
1 mg/5ml Syrup
Inhale a dose of 0.63 mg three times daily
Inhaler
50 mcg
Syrup
1 mg/5ml Syrup
Asthma
For 2 to 12 years old:
Inhale a dose of 0.31 mg three times daily
For >12 years old:
Inhale a dose of 0.63 mg three times daily
Beta-Blockers decrease the effect of bronchiodilation of Beta2-Agonists
Beta-Blockers decrease the effect of bronchiodilation of Beta2-Agonists
Beta-Blockers decrease the effect of bronchiodilation of Beta2-Agonists
Beta-Blockers decrease the effect of bronchiodilation of Beta2-Agonists
Beta-Blockers decrease the effect of bronchiodilation of Beta2-Agonists
may increase the adverse effect of other beta2-agonists
may increase the adverse effect of other beta2-agonists
may increase the adverse effect of other beta2-agonists
may increase the adverse effect of other beta2-agonists
may increase the adverse effect of other beta2-agonists
levosalbutamol: they may increase the CNS depressant effect of CNS Depressants
levosalbutamol: they may increase the CNS depressant effect of CNS Depressants
levosalbutamol: they may increase the CNS depressant effect of CNS Depressants
levosalbutamol: they may increase the CNS depressant effect of CNS Depressants
levosalbutamol: they may increase the CNS depressant effect of CNS Depressants
levosalbutamol: they may decrease the therapeutic effect of anticholinesterases
levosalbutamol: they may decrease the therapeutic effect of anticholinesterases
levosalbutamol: they may decrease the therapeutic effect of anticholinesterases
levosalbutamol: they may decrease the therapeutic effect of anticholinesterases
levosalbutamol: they may decrease the therapeutic effect of anticholinesterases
may decrease the bronchodilatory effect of beta2-agonists
may decrease the bronchodilatory effect of beta2-agonists
may decrease the bronchodilatory effect of beta2-agonists
may decrease the bronchodilatory effect of beta2-agonists
may decrease the bronchodilatory effect of beta2-agonists
may increase the adverse effect of other beta2-agonists
may increase the adverse effect of other beta2-agonists
may increase the adverse effect of other beta2-agonists
may increase the adverse effect of other beta2-agonists
may increase the adverse effect of other beta2-agonists
may decrease the bronchodilatory effect of beta2-agonists
may decrease the bronchodilatory effect of beta2-agonists
may increase the toxic effect of beta2 agonists
may decrease the bronchodilatory effect of beta blockers
may decrease the bronchodilatory effect when combined with beta2-agonists
may decrease the bronchodilatory effect when combined with beta2-agonists
may decrease the bronchodilatory effect when combined with beta2-agonists
may decrease the bronchodilatory effect when combined with beta2-agonists
may decrease the bronchodilatory effect when combined with beta2-agonists
may decrease the bronchodilatory effect when combined with beta2-agonists
may decrease the bronchodilatory effect when combined with beta2-agonists
may decrease the bronchodilatory effect when combined with beta2-agonists
may decrease the bronchodilatory effect when combined with Beta2-Agonists
may decrease the bronchodilatory effect when combined with Beta2-Agonists
may decrease the bronchodilatory effect when combined with Beta2-Agonists
Beta2-Agonists: they mayincrease the hypokalemic effect when combined with thiazides
Beta2-Agonists: they mayincrease the hypokalemic effect when combined with thiazides
Beta2-Agonists: they mayincrease the hypokalemic effect when combined with thiazides
Beta2-Agonists: they mayincrease the hypokalemic effect when combined with thiazides
Beta2-Agonists: they may increase the hypokalemic effect of loop diuretics
Beta2-Agonists: they may increase the hypokalemic effect of loop diuretics
Beta2-Agonists: they may increase the hypokalemic effect of loop diuretics
When levosalbutamol is used together with ouabain, this leads to reduction in levosalbutamol excretion
may increase the hypokalemic effect of thiazide diuretics
may increase the hypokalemic effect of thiazide diuretics
may increase the adverse effect of monoamine oxidase inhibitors
may increase the adverse effect of monoamine oxidase inhibitors
may increase the adverse effect of monoamine oxidase inhibitors
may increase the adverse effect of monoamine oxidase inhibitors
may increase the adverse effect of monoamine oxidase inhibitors
spironolactone and hydrochlorothiazide
may increase the hypokalemic effect when combined with diuretics
may increase the hypokalemic effect when combined with diuretics
may increase the hypokalemic effect when combined with diuretics
may increase the hypokalemic effect when combined with diuretics
may increase the hypokalemic effect when combined with diuretics
may decrease the bronchodilatory effect of beta blockers
may have an increased tachycardic effect when combined with beta2-agonists
atosiban: they may increase the toxic effect of Beta2-Agonists
theophylline derivatives: they may increase the toxic effect of Beta2-Agonists
may have an increasingly adverse effect when combined with beta2-agonists
may have an increasingly adverse effect when combined with beta2-agonists
may have an increasingly adverse effect when combined with beta2-agonists
may have an increasingly adverse effect when combined with beta2-agonists
may have an increasingly adverse effect when combined with beta2-agonists
may have an increasingly adverse effect when combined with beta2-agonists
may have an increasingly adverse effect when combined with beta2-agonists
may have an increasingly adverse effect when combined with beta2-agonists
may have an increasingly adverse effect when combined with beta2-agonists
may increase the hypokalemic effect of beta2-agonists
may increase the hypokalemic effect of beta2-agonists
may increase the hypokalemic effect of beta2-agonists
Action and Spectrum:
Beta-2 adrenoceptor agonists initiate adenylate cyclase to produce cyclic AMP (cAMP), in which airway smooth muscle cells leads to relaxation.
These agents relieve bronchospasm and reduce airway resistance and connects with beta-2 adrenergic receptors on smooth muscle of bronchial tissue.
Adverse reaction:
Black box warning:
None
Contraindications/caution:
Pregnancy Warnings:
Pregnancy category: N/A
Lactation: Excretion of the drug into the human breast milk is unknown
Pregnancy categories:
Pharmacology:
Cyclic AMP activates protein kinase A, which inhibits myosin phosphorylation.
Beta-agonists stimulate the beta-2 adrenergic receptor on cell surfaces, causes smooth muscle relaxation.
Pharmacodynamics:
Levosalbutamol relaxes airway muscles, which improves air flow in the lungs. It works as a bronchodilator medicine.
Adrenergic receptors activate bronchodilation via cAMP messenger system.
Administration:
It is administered via inhaler.
Patient information leaflet:
Generic Name: Levosalbutamol
Why do we use Levosalbutamol?
Levosalbutamol is used in the treatment of asthma and chronic obstructive pulmonary disease (COPD).
It is also used in management of bronchospasms and lung inflammation.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
